pophosphatemia-mediated hypotension in transgenic mice overexpressing human FGF-23. Am J Physiol Heart Circ Physiol 297: H1514 -H1520, 2009. First published August 14, 2009 doi:10.1152/ajpheart.00581.2009) is a potent circulating phosphaturic factor associated with renal phosphate wasting. The effects of FGF-23 on skeletal and phosphate homeostasis have been investigated widely; however, the effect of FGF-23 on the cardiovascular system (CVS) is unknown. To assess whether FGF-23 influences the function and structure of the CVS and whether the effect of FGF-23 on the CVS is mediated by FGF receptors directly or indirectly by hypophosphatemia, FGF-23 transgenic mice and their wild-type littermates were fed a normal diet or a high-phosphate diet comprising a normal diet plus 1.25% phosphate in drinking water from weaning for 5 wk, and the phenotypes of the CVS were compared between FGF-23 transgenic mice and their wild-type littermates on the same diet. At the end of this time period, transgenic animals on the normal diet developed hypotension. The left ventricle was appropriately hypertrophic, and plasma catecholamine and renin-angiotensin system components were upregulated, indicating compensatory mechanisms in response to the hypotension. Transgenic mice also exhibited an impaired vascular reactivity and a downregulation of vasoconstrictor receptor gene expression, possibly as pathogenetic factors contributing to the hypotension. The high-phosphate diet improved the hypophosphatemia, resulting in a rescue of the cardiovascular phenotype. This study demonstrates that FGF-23 overexpression can result in abnormalities in the CVS and that the effect of FGF-23 overexpression on the CVS is mediated by the secondary severe hypophosphatemia.
FIBROBLAST GROWTH FACTOR-23 (FGF-23) is a recently identified polypeptide hormone, sharing a common core region with the FGF family and belonging to the FGF-19 subfamily (20) . FGF-23 protein is composed of 251 amino acids with the NH 2 -terminal 24 amino acids functioning as a signal peptide. Genetic studies have identified missense mutations in FGF-23, resulting in autosomal-dominant hypophosphatemic rickets (ADHR). Furthermore, ADHR, X-linked phosphatemic rickets, and tumor-induced osteomalacia share common clinical and biochemical features characterized by hypophosphatemia resulting from renal phosphate wasting and low 1,25-dihydroxyvitamin D [1, 25(OH) 2 D] levels. Current evidence suggests that these common biochemical features are all due to the increased activity of FGF-23, indicating that this polypeptide plays a critical role in the maintaining of both phosphate homeostasis and vitamin D metabolism (21, 28, 29, 31) .
The control of serum phosphate concentrations, which is the major and most well-known function of FGF-23, largely results from the downregulation of the renal sodium phosphate cotransporter protein IIa, located within the apical membrane of the proximal tubule (21) . The decreased circulating levels of 1,25(OH) 2 D, despite the presence of hypophosphatemia, is mainly due to the suppression by FGF-23 of the 25-hydroxyvitamin D 1␣-hydroxylase enzyme and to the activation of the 25-hydroxyvitamin D 24-hydroxylase enzyme in the proximal tubule (3, 21) . Recently, Miyamoto et al. (13) demonstrated that FGF-23 reduces intestinal sodium phosphate cotransporter protein IIb activity mediated by the 1,25(OH) 2 D/vitamin D receptor system, resulting in an impaired phosphate absorption from the small intestine, thus providing further insight into the mechanisms by which FGF-23 regulates phosphate homeostasis. Taken together, these studies indicate that phosphaturia coupled with reduced phosphate absorption from the small intestine leads to hypophosphatemia.
It is well established that inorganic phosphate is an essential element for cellular metabolism and bone mineralization and plays a vital role in a number of other biological processes such as signal transduction, nucleotide metabolism, and enzyme regulation. A decrease in phosphate can lead to a depletion in cellular ATP, which may account for neurological and muscular symptoms. Studies of the effect of hypophosphatemia on the cardiovascular system (CVS) have been ongoing for several decades. It has been demonstrated that phosphate depletion can decrease mean arterial pressure and cardiac index in rats (18) . In the clinic, however, the results are somewhat controversial. Vered et al. (26) reported that cardiovascular symptoms and left ventricular dysfunction were absent in patients with chronic hypophosphatemia, whereas others (7, 17) have demonstrated that chronic severe hypophosphatemia can induce reversible myocardial depression in humans.
FGF-23 can signal to target cells by binding and activating cell-surface tyrosine kinase FGF receptors (FGFRs). Among the seven canonical FGFR isoforms, it has been demonstrated that FGF-23 bound only the c splice isoforms of FGFR1-3, as well as FGFR4 (30) , indicating that FGF-23 may activate several FGFR isoforms in vivo to produce physiological responses. In addition, Klotho protein acts as a cofactor for FGF-23 to facilitate the binding of FGF-23 to FGFR1c, -3c, and -4 (1, 11, 25) . Despite the fact that the widespread distribution of FGFRs has been demonstrated in both heart and arteries, Klotho protein expression is more restricted, and its expression has been noted particularly in the renal distal convoluted tubule, the parathyroid gland, and the epithelium of the choroid plexus in the brain. In the CVS, Klotho is only expressed in the sinoatrial node, where it is essential for the sinoatrial node to function as a dependable pacemaker under conditions of stress (23) . It is unclear therefore whether the effect of FGF-23 on the CVS is mediated by FGFRs directly or by hypophosphatemia indirectly.
We have previously reported a mouse model overexpressing and secreting from the liver, human FGF-23 (R176Q) (2), a mutant form that fails to be degraded by furin-like proteases. These animals showed more pronounced hypophosphatemia and rickets/osteomalacia than animals expressing the wild-type FGF-23 due to prolonged biological half-life (3). However, the effect of FGF-23 overexpression on the CVS is unknown.
To assess whether FGF-23 alters the function and structure of the CVS and whether the effect of FGF-23 on the CVS is mediated by FGFRs directly or by hypophosphatemia indirectly, FGF-23 transgenic mice and their wild-type littermates were fed a normal diet or a high-phosphate diet containing a normal diet plus 1.25% phosphate in the drinking water from weaning for 5 subsequent wk, and the phenotypes of the CVS were compared between FGF-23 transgenic mice and their wild-type littermates on the same diets.
MATERIALS AND METHODS

Animals and treatment.
The generation and genotyping of transgenic mice overexpressing human FGF-23 (R176Q) were performed as described previously (2) . Transgenic mice were generated through the breeding of transgenic male mice and wild-type female mice and determined by PCR analysis of DNA from tail biopsies, and the wild-type littermates were used as controls in all experiments. All mice were housed in a specific pathogen-free barrier facility in a regular 12-h:12-h light/dark cycle and fed an autoclaved standard rodent chow. After weaning, sex-matched transgenic and wild-type pups were fed a normal diet containing 1% calcium (wt/wt) and 0.67% phosphorus (wt/wt) or a high-phosphate diet containing a normal diet plus 1.25% KH 2PO4 (wt/vol) in drinking water for 5 subsequent wk. The use of animals in this study was approved by the Institutional Animal Care and Use Committee of the University.
Measurement of blood pressure. The noninvasive computerized tail-cuff blood pressure system (ML125 NIBP system, PowerLab) was used to obtain systolic blood pressure on conscious animals as described previously (32) . Mice were trained for 7 days to habituate to the apparatus and restraint before the measurement. All training and measurements were performed between 8:00 AM and 11:00 AM each day. To obtain accurate recordings of blood pressure, extreme care in handling the mice was needed, and the mice remained at a still and unperturbed status during the measurement period. The chamber was kept at 31-33°C. Systolic blood pressure was measured for 3 consecutive days, and 10 separate determinations of systolic blood pressure were made per mouse per day. The mean systolic blood pressure for each mouse was calculated by averaging the daily blood pressure of each mouse over the 3 consecutive days of readings.
Echocardiographic analysis. Transthoracic echocardiography was performed using a 14.0-MHz imaging transducer (Vivid 7 GE Medical Systems) as described previously (32) . Mice were lightly anesthetized with 7.5% chloral hydrate (5 l/g ip), and the left anterior chests were shaved carefully. A warming pad was used to maintain body temperature. The left ventricle was imaged in the two-dimensionally guided M-mode at the level of the papillary muscles from the parasternal long-axis view. Left ventricular end-diastolic dimension (LVDd), left ventricular end-systolic dimension, left ventricular posterior wall thickness diastolic (LVPWd), interventricular septum thickness diastolic (IVSd), and heart rate were measured directly. Left ventricular ejection fraction was calculated by Teichholz formula. Left ventricular mass was calculated as 1.055
. All measurements were collected by the leading-edge method as recommended by the American Society of Echocardiography.
Measurements of serum and urine parameters. Serum glucose, phosphate, calcium, sodium, and potassium concentrations and urine concentrations of phosphate, calcium, and sodium were determined using an autoanalyzer. Concentrations of mouse plasma catecholamine (epinephrine, norepinephrine, and dopamine), renin-angiotensin system (RAS) components (renin, angiotensin II, and aldosterone), and cortisol were determined by radioimmunoassay, using commercial radioimmunoassay kits as described previously (32) . All procedures were performed according to the manufacturer's instructions.
Determination of ventricular ATP content. The left ventricular ATP content was measured by the ATP Bioluminescence Assay kit (Sigma) according to the manufacturer's protocol. Briefly, freshly dissected samples were rapidly homogenized in deionized water (pH 7.8) and centrifuged for 15 min at 3,000 rpm. The samples were kept on ice until measurements were performed. For a determination of ATP, the standards or the supernatants were mixed with 100 l of luciferase reagent, and ATP was measured with a luminometer (LuminMax-C, MSI). A standard curve with purified ATP was used to calculate tissue concentrations.
Aortic ring assay. Mice from each group were anesthetized by a peritoneal injection with 5 l/g of 7.5% chloral hydrate and euthanized by cervical dislocation. The thoracic aorta was quickly removed and transferred to ice-cold oxygenated (95% O2-5% CO2) KrebsHenseleit solution where perivascular fat and connective tissue were removed. Aortic ring segments (1-1.5 mm in length) were then cut and equilibrated at a resting tension of 1 g for 60 min before the experiments. The composition (in mM) of the Krebs-Henseleit solution was 119 NaCl, 4.7 KCl, 1.18 KH 2PO4, 25 NaHCO3, 1.19 MgSO 4, 2.5 CaCl2, and 11.0 glucose. The volume of the bath solution was 10 ml, and the bath temperature was maintained at 37°C. Aortic ring contractile force was measured isometrically as previously described (8) . Following the equilibration period, the rings were maximally stimulated with 120 mM KCl. Subsequently, the rings were allowed to equilibrate for another hour, with the Krebs-Henseleit solution being changed every 15 min. Cumulative response curves were obtained for norepinephrine (range, 10 Ϫ9 -10 Ϫ6 M; SigmaAldrich) or angiotensin II (range, 10 Ϫ9 -10 Ϫ6 M; Sigma-Aldrich). At 
␣1-AR, ␣1-adrenergic receptor; AT1A, angiotensin II receptor 1A.
the end of the experiment, the viability of the aortic rings was evaluated by an additional KCl load (120 mM). RNA extraction and real-time PCR. Total RNA was extracted from mouse descending aorta using TRIzol reagent (Invitrogen), and 1 g RNA was reverse transcribed to cDNA according to the manufacturer's recommendations. Quantitative real-time PCR reactions were performed with SYBR Green PCR reagent kit (Toyobo) on an Applied Biosystems Cycler, using 1 l of cDNA as the template in each 25-l reaction mixture. The primer sequences for mouse ␣ 1-adrenergic receptor (␣1-ARs), angiotensin II receptor 1A (AT1A), and GAPDH genes were listed in Table 1 . The specificity of the primers was verified by sequence analysis using the Basic Local Alignment Search Tool (BLAST) program. The protocol of amplification consisted of an initial 4 min at 94°C followed by 40 cycles of a three-step loop: 30 s at 94°C, 30 s at 55°C, and 45 s at 72°C. To confirm the specificity of PCR products, melting curve analysis and standard gel electrophoresis were performed. The results were analyzed with the SDS 7500 software and normalized with the quantity of GAPDH mRNA to correct for sample variability.
Statistical analysis. All data were expressed as means Ϯ SE. Multiple group comparisons were analyzed by one-way ANOVA followed by a Tukey-Kramer test. Values of P Ͻ 0.05 were considered statistically significant.
RESULTS
FGF-23 overexpression resulted in hypotension and cardiac hypertrophy.
To assess the effects of FGF-23 on systolic blood pressure and cardiac systolic function, the systolic blood pressure was measured using a noninvasive computerized tail-cuff system and cardiac systolic function was examined by echocardiography in FGF-23 transgenic mice and their wild-type littermates. The results showed that for mice on a normal diet, the mean systolic blood pressure was decreased by 17% in transgenic mice compared with their wild-type littermates (Fig. 1) . Echocardiographic analyses revealed that IVSd, LVPWd, and left ventricular mass relative to body weight were increased; however, the left ventricular ejection fraction and heart rate, indexes of cardiac systolic function, were not altered significantly in FGF-23 transgenic mice compared with sex-matched wild-type littermates (Table 2) . We next examined whether transgenic mice developed cardiomyocyte hypertrophy, interstitial fibrosis, and heart energy failure by histology, histochemistry, and ATP assay, respectively. The cardiomyocyte diameter and fibrosis were not increased significantly (data not shown), whereas ATP was not reduced significantly compared with their wild-type littermates (Table 4 ). These data demonstrated that FGF-23 overexpression induced hypotension and cardiac hypertrophy but had not affected cardiac systolic function, structure, and energy metabolism.
FGF-23 overexpression resulted in upregulation of plasma catecholamines and the RAS. To determine whether hypotension was associated with the disorders of catecholamines and the RAS in transgenic mice overexpressing FGF-23, plasma epinephrine, norepinephrine, dopamine, renin, angiotensin II, aldosterone, and cortisol were determined by radioimmunoassay. The results showed that plasma epinephrine, norepinephrine, dopamine, angiotensin II, and cortisol (Table 3) were Values are means Ϯ SE of determinations in 12 animals of each group. NDWT, wild-type mice fed a normal diet; NDTG, FGF-23 transgenic mice fed a normal diet; HPWT, wild-type mice fed a high-phosphate diet; HPTG, FGF-23 transgenic mice fed a high-phosphate diet; HR, heart rate; IVSd, interventricular septum thickness diastolic; LVPWd, left ventricular posterior wall thickness diastolic; LVDd, left ventricular end-diastolic dimension; LVDs, left ventricular end-systolic dimension; LVM, left ventricular mass; LVEF, left ventricular ejection fraction. IVSd, LVPWd, LVDd, LVDs, and LVM were normalized to body weight. *P Ͻ 0.01 compared with wild-type mice. upregulated significantly in FGF-23 transgenic mice compared with their wild-type littermates. Aldosterone levels were raised insignificantly in FGF-23 transgenic mice. These results demonstrated that FGF-23 overexpression induced the activation of catecholamines and the RAS, suggesting that the upregulation of catecholamines and the RAS were compensatory responses to the hypotension.
FGF-23 overexpression impaired vascular reactivity and downregulated expression of vasoconstrictor receptors.
To further investigate the mechanism of hypotension caused by FGF-23 overexpression, the vascular reactivity was examined in vitro using aortic rings from mice on a normal diet. The results showed that the responses to increasing doses of norepinephrine ( Fig. 2A) and angiotensin II (Fig. 2B) were significantly lower in the aortic rings from FGF-23 transgenic mice than in those from wild-type mice. However, the maximal contraction induced by KCl (Fig. 2C) was similar in aortic rings from FGF-23 transgenic and wild-type mice. These results indicate that FGF-23 overexpression results in a decreased vascular reactivity to vasoconstrictors.
To determine whether the reduction of the vascular reactivity was associated with the downregulation of vasoconstrictor receptors, three ␣ 1 -AR subtypes and AT 1A mRNA levels were examined by real-time RT-PCR. The results revealed that the expression of the three subtypes of ␣ 1 -ARs and AT 1A mRNA (Fig. 2, D-G) were downregulated significantly in aortas from FGF-23 transgenic mice on a normal diet relative to those from wild-type mice, suggesting that FGF-23 overexpression resulted in the downregulation of vasoconstrictor receptors.
The abnormalities of the CVS induced by FGF-23 overexpression were rescued by a high-phosphate diet following improved hypophosphatemia. To determine whether the effect of FGF-23 on the CVS is mediated by FGFRs directly or by hypophosphatemia indirectly, 3-wk-old postweaning, sexmatched wild-type and FGF-23 transgenic mice were fed a high-phosphate diet containing a normal diet plus 1.25% phosphate in the drinking water for 5 subsequent wk. Serum, plasma, and urine analytes; plasma catecholamine and RAS levels; systolic blood pressure; cardiac systolic function; vascular reactivity; and vasoconstrictor receptors were examined. The results showed that the hypotension (Fig. 1 ) and cardiac hypertrophy (Table 2 ) were rescued; the plasma catecholamine, RAS and cortisol (Table 3) , were reduced significantly; serum glucose (Table 4) , the vascular reactivity (Fig. 2, A and  B) , and vasoconstrictor receptor mRNA levels (Fig. 2, D-G) were increased significantly. Although serum phosphorus levels (Table 4) were not normalized in FGF-23 transgenic mice by the high-phosphate diet intake, they were significantly higher than those levels from the normal diet. These findings suggest that the effect of FGF-23 overexpression on the CVS is mediated by the secondary severe hypophosphatemia, but not mediated by FGFR.
DISCUSSION
In the present study, we employed a genetic approach to determine the effect of FGF-23 overexpression on the CVS. Our results demonstrated that mice overexpressing FGF-23, fed a normal diet, developed hypotension, cardiac hypertrophy, impaired vascular reactivity, as well as downregulation of vasoconstrictor receptors, at 8 wk of age. The high-phosphate diet improved serum phosphorus levels and not only rescued blood pressure and cardiac hypertrophy but also normalized the vascular reactivity, vasoconstrictor receptor mRNA expression levels, and plasma catecholamine and RAS in FGF-23 transgenic mice. These data, therefore, suggest that the effect of FGF-23 overexpression on the CVS is mediated by the secondary severe hypophosphatemia.
FGF-23 is a potent circulating phosphaturic factor. Consistent with this notion, we confirmed that serum phosphorus levels were decreased significantly in FGF-23 transgenic mice receiving the normal diet compared with their wildtype littermates. However, the serum calcium levels were not altered. The retention of normal serum calcium in the face of hypophosphatemia has been shown to occur previously in both FGF-23 transgenic mouse models (12, 22) and hypophosphatemic ADHR patients with missense mutations in FGF-23. This may indicate that interactions not only among the classic calcium regulating hormones parathyroid hormone and 1,25(OH) 2 D but also potentially with ␣-Klotho and FGF-23 (14, 15) coordinate to maintain serum calcium within the normal range (25) . Irrespective of the precise mechanism, however, alterations in serum calcium could not have contributed to the cardiovascular changes observed.
In contrast to the serum calcium, the serum glucose levels were slightly but significantly decreased in transgenic mice fed a normal diet compared with their wild-type littermates. Interestingly, FGF-23 null mice also displayed hypoglycemia due to an increase of insulin sensitivity and glucose tolerance (9) . Because inorganic phosphate plays a vital role in a number of metabolic processes (4), the altered glucose metabolism in these mice could be a secondary effect of the abnormal serum phosphate levels, and indeed serum glucose was normalized in transgenic mice fed a high-phosphate diet. The degree of glucose reduction in these animals, however, seemed unlikely to play a major deleterious role in CVS function.
In this study, we found that FGF-23 transgenic mice fed a normal diet displayed a 17% decrease in mean systolic blood pressure. It is well established that plasma catecholamine and RAS levels are closely correlated to blood pressure levels. Furthermore, reduced catecholamine levels can cause hypotension (33) . In contrast, we found that plasma catecholamine and RAS levels were not decreased but were raised in FGF-23 transgenic mice relative to their wild-type littermates receiving a normal diet. These results suggest that alterations in catecholamines and the RAS are not causal but are responsive factors in FGF-23 transgenic mice. Thereby, we examined vascular sensitivity by using aortic rings in vitro and found decreased vascular sensitivity to norepinephrine and to angiotensin II, but not to KCl. Norepinephrine-and angiotensin II-induced contractile responses of vascular smooth muscle are receptor mediated, whereas KCl responses are voltage operated. This suggested that these changes might be associated with the downregulation of expression of vasoconstrictor receptors.
␣ 1 -ARs (␣ 1A , ␣ 1B , and ␣ 1D ) are regulators of systemic arterial blood pressure and blood flow (6) , although the vasoconstricting action of the ␣ 1B -AR subtype is controversial (5, 33) . In addition, angiotensin II, the major bioactive peptide in the RAS that plays a key role in cardiovascular homeostasis, exerts its multiple effects through different types of AT receptors. Most of the known physiological and pathophysiological effects of angiotensin II are mediated via the AT 1 (16, 19, 24, 27) , and the AT 1A subtype is predominantly expressed in the CVS (10) . Therefore, we examined the gene expression of the three subtypes of ␣ 1 -ARs and AT 1A by real-time RT-PCR. Our results revealed that the expression of ␣ 1 -AR subtypes and AT 1A mRNA were downregulated significantly in FGF-23 transgenic mice receiving the normal diet compared with their wild-type littermates. These findings indicate that a reduction of these vasoconstrictor receptors are, at least in part, contributing to hypotension caused by FGF-23 overexpression with severe hypophosphatemia.
To determine whether abnormalities of the CVS occurring in FGF-23 transgenic mice were secondary to the severe hypophosphatemia, FGF-23 transgenic mice were fed a highphosphate diet from weaning for 5 wk. Following an improvement of the hypophosphatemia, not only blood pressure and cardiac hypertrophy but also vascular reactivity, vasoconstrictor receptor mRNA expression levels, and levels of plasma catecholamines and components of the RAS were normalized in mutant FGF-23 transgenic mice. These data suggest that the effect of mutant FGF-23 overexpression on the CVS is mediated via the secondary severe hypophosphatemia.
The phenotypes of FGF-23 transgenic mice fed the normal diet resemble that of phosphate-depleted animals. Nevertheless, our findings of reduced gene expression of ␣ 1 -ARs and AT 1 receptors were not observed in a previous report (18) . Thus, although we found that the gene expression of ␣ 1 -ARs and AT 1 receptors was downregulated in the aortas of FGF-23 transgenic mice, no alterations in content and affinity of ␣-and ␤-ARs were observed in hearts from phosphate-depleted rats (18) . This inconsistency may result from differences in the methods used to quantitate mRNA levels. A second difference may be the duration of hypophosphatemia in the two models. Thus FGF-23 transgenic mice experienced severe hypophosphatemia chronically from the time of weaning, whereas the rats were subjected to a low-phosphate diet at an older age. The chronicity of the hypophosphatemia in the FGF-23 transgenic mice may also have made the animals more tolerant to the cardiac effects of hypophosphatemia so that an impairment of the cardiac index was not observed. This is also in keeping with the absence of LV dysfunction in children with lifelong hypophosphatemia (26) in contrast to those with acquired hypophosphatemia (7, 17) .
In summary, we employed a genetic approach to determine the effect of mutant FGF-23 overexpression on the CVS. Our results demonstrated that mutant FGF-23 overexpression resulted in hypotension, which was associated with an impaired vascular reactivity and downregulation of vasoconstrictor receptors, whereas the hypertrophy of the left ventricle and the upregulation of plasma catecholamine and RAS activities may have resulted from protective responses to the hypotension. The high-phosphate diet improved the hypophosphatemia, resulting in the rescue of the cardiovascular phenotype. This study, therefore, demonstrates that mutant FGF-23 overexpression can result in functional abnormality in the CVS and suggests that the effect of the mutant FGF-23 overexpression on the CVS is mediated by the secondary severe hypophosphatemia.
